pharmaceutical outcomes research & …...lou garrison, phd, assumes the role of president for...

PHARMACEUTICAL OUTCOMES RESEARCH & POLICY PROGRAM

PORPP ANNUAL REPORT

FALL 2016

UWSOP faculty and alumni represent past, present and future leaders of ISPOR. (From left to right) Past President (2003-2004) Sean D. Sullivan, President Lou Garrison, President-elect Shelby Reed, Immediate Past President Daniel Malone, Past President (2010-2011) Scott Ramsey.

August 10, 2016 MESSAGE FROM ANIRBAN BASU, PhD Stergachis Family Endowed Director & Professor

The twentieth year of PORPP has been special. This annual report highlights some of those accomplishments and special moments. As in previous years, PORPP continues to grow in number and in the achievements of its talented and dedicated members working collabo-ratively across a wide range of disciplines. We remain ever grateful to PORPP’s founding members, alumni and our corporate advisors, whose continued support is instrumental to our success in the future. The success of our program is best highlighted by our cover picture that shows the contributions of our program to the past, present and future leadership of ISPOR.

This past year brought another exceptionally strong year of achieve-ments for our program. Several of our students won university-wide,

national and international accolades. Just to highlight a few, Blythe Adamson received a pre-doctoral fellowship from the American Foundation of Pharmaceutical Education, while William Canestaro’s paper was awarded the JMCP 2015 Award for Excellence. A list of all student awards can be found on Page 18. In the 2016 ISPOR Annual meeting, Research Assistant Pro-fessor Aasthaa Bansal won the best poster award by a new investigator, while alumnus Joshua Roth won the best podium by a new investigator. Post-doc Kai Yeung won the best paper award at the Vancouver Health Economics Meeting in 2016. A list of faculty awards can also be found on page 18.

Starting from April 2016, Dave Veenstra transitioned into the role of Associate Director for the program. We are grateful for his long-running service as the Director of the Graduate Program in PORPP and helping to evolve it to one of the premier health economics and outcomes research graduate programs in the country. Beth Devine has taken up the role as the Director of the Grad-uate Program. Beth has long been intellectually engaged with the graduate program and its stu-dents. She has a strong history of using advanced quantitative (population health) and qualita-tive (mixed) methods in a variety of health services research works. Her unique skills in bridging these two important pillars of health services research will bring tremendous value in leading the graduate program. Josh Carlson, a newly tenured Associate Professor, will serve as the Associ-ate Director of the Graduate Program. We also welcomed Prof. H. Steve White, a nationally renowned pharmacologist and a leader in translational research in anticonvulsant drug therapies, as the chair of the Department of Pharmacy.

Our training programs are going strong. For this coming year, we are admitting another strong new graduate program cohort. The admissions committee has recruited our top candidates, who are profiled here. Our Distance Learning Certificate in Health Economics and Outcomes Re-search will welcome another large batch of students this fall. We have now trained nearly 260 students through this mechanism.

Commemorating the twentieth year of PORPP, we held a one-and-half day, well-attended, re-treat to brainstorm and develop a revised set of strategic goals for our program. We also reached out to all our affiliate and adjunct faculty members, alumni and corporate advisory board mem-bers for their views on the strategic goals of the program. We are in the process of assimilating all their feedback and developing a plan for the future.

I thank all of our past and present Corporate Advisory Board members for their continued sup-port to the program. The Outcomes CAB also celebrated its fifteenth anniversary this year and we cherish their engagement to the program. Finally, I want to thank Penny Evans and Paul Kraegel, our superb program and research coordinators, who help to make all of this possible.

Table of Contents A Legacy of Leadership - - - - - - 3 New Alumni - - - - - - - 4 Incoming Students & Fellows - - - - - 5 Certificate Programs - - - - - - 6 Current Students & Fellows - - - - - - 7 Enterprising Student - - - - - - 9 PORPP Prize 2016 - - - - - - - 11 PORPP Leadership Updates - - - - - - 12 Biomedical Regulatory Affairs - - - - - 12 Faculty Milestone - - - - - - - 13 Research Highlights - - - - - - 14 PORPP in Developing Countries - - - - - 15 Post-Doctoral Fellows - - - - - - 16 Junior Faculty - - - - - - - 17 Honors & Awards - - - - - - - 18 Student Publications & Posters - - - - - 18 Post-Doc Publications - - - - - - 19 Faculty Publications - - - - - - 19 2016 PORPP Retreat - - - - - - 20 Faculty Grants - - - - - - - 22 Gift Acknowledgements - - - - - - 24

UW SOP FACULTY & ALUMNI ELECTED TO ISPOR LEADERSHIP

Five UWSOP faculty and alumni have led ISPOR over the past 20 years

By Sarah Guthrie

PORPP Faculty

Joseph Babigumira, MBChB, MS, PhD Adjunct Assistant Professor

Aasthaa Bansal, PhD Research Assistant Professor

Anirban Basu, PhD

Stergachis Family Endowed Director & Professor, Pharmaceutical Outcomes Research & Policy Program

Caroline Bennette, MPH, PhD Acting Assistant Professor

Brian Bresnahan, PhD Adjunct Research Assistant Professor

Josh Carlson, MPH, PhD Associate Professor, Associate Director, Graduate Programs

Beth Devine, PharmD, MBA, PhD Associate Professor, Director, Graduate Programs

David Flum, MD, MPH Adjunct Professor

Louis Garrison, Jr., PhD Professor Emeritus

Bernardo Goulart, MD, MS Adjunct Assistant Professor

Shelly Gray, PharmD, MS Professor

Ryan Hansen, PharmD, PhD Research Assistant Professor

Thomas Hazlet, PharmD, DrPH Associate Professor

Jerry Jarvik, MD, MPH Adjunct Professor

Larry Kessler, ScD Adjunct Professor

Gary Lyman, MD, MPH Adjunct Professor Co-Director, HICORE (Hutchinson Institute for Cancer Outcomes Research and Evaluation), Fred Hutchinson Cancer Research Center

Zachary Marcum, PharmD, MS, PhD

Assistant Professor

Jeannine McCune, PharmD Professor

Donald Patrick, PhD

Adjunct Professor, Dept. of Health Services

Scott Ramsey, MD, PhD Adjunct Professor, Director, HICORE (Hutchinson Institute for Cancer Outcomes Research and Eval-uation), Fred Hutchinson Cancer Research Center

Andy Stergachis, PhD Professor, Associate Dean for Research, Graduate Education & New Initiatives

Lotte Steuten, PhD Adjunct Associate Professor Associate Member, Hutchinson Institute for Cancer Outcomes Research and Evaluation

Sean Sullivan, PhD,

Dean of the School of Pharmacy

David Veenstra, PharmD, PhD Professor, Associate Director, PORPP

Davene Wright Assistant Professor, Pediatrics Adjunct Assistant Professor, Pharmacy

Staff Penny Evans Graduate Program Advisor Laurie Gold, PhD Research Scientist Paul Kraegel, MSW Program Operations Specialist

UW SOP FACULTY & ALUMNI ELECTED TO ISPOR LEADERSHIP

Five UWSOP faculty and alumni have led ISPOR over the past 20 years

By Sarah Guthrie

UW School of Pharmacy faculty and alumni are again recognized as leaders in health care. The International Society for Pharmacoeconomics and Outcomes Re-search (ISPOR) announced the election of the Socie-ty’s 2016-2017 Board of Directors that assumed office on July 1, 2016. Many of the new leadership team are part of the UW School of Pharmacy family. This recent election marks an historic time when UW School of Pharmacy is represented in the past, current and future presidential leadership roster for ISPOR, showcasing our outstanding alumni and preeminent faculty.

Lou Garrison, PhD, assumes the role of President for 2016-17 after most recently serving as the Society’s President-Elect. Lou is a highly-respected Professor in the Pharmaceutical Outcomes Research and Policy Program in UWSOP. “I am honored and privileged to have the opportunity to serve as President of ISPOR this coming year as we enter our third decade. My pri-orities will be: supporting our global network to expand capacity in outcomes research, continuing to improve the science of outcomes research through our task forces and journals, and collaborating with allied organ-izations, such as ASHEcon, HTAi, AMCP, DIA, SMDM, and AcademyHealth.” Daniel C. Malone, RPh, PhD, who had completed his post doc work at UWSOP, becomes Immediate Past President. Dan serves as Professor of Pharmacy, Col-lege of Pharmacy and Associate Professor in Mel and Enid Zuckerman College, University of Arizona in Tuc-son, Arizona. ISPOR’s global membership elected Shelby D. Reed, RPh, PhD, who had also completed her post doc work here at UWSOP, to serve as President-Elect for the Society for 2016-17.

PORPP /

Shelby is Professor, Duke University in Durham, North Carolina. With Shelby’s election as ISPOR President-elect, UW School of Pharmacy has five faculty and alumni who have gone on to serve as President of ISPOR. The new ISPOR Board of Directors also now includes alumnus John Watkins, MPH, PharmD, ’79, ’11, For-mulary Manager, Premera Blue Cross in Mountlake Terrace, Washington. John received the UWSOP’s Award for Excellence in Clinical Teaching in 2014 for being an exemplary practitioner, role model, coach, facilitator, and team player for over 20 years. ISPOR is an organization with tremendous influence in global health economics. In the words of our own Lou Garrison: ISPOR has “over 20,000 members in some 120 countries. When you absorb that fact, you realize that ISPOR as an organization has tremendous poten-tial to have a positive impact on health globally—and not just by sheer numbers but also by the quality of our science. The medical product and decision processes that ISPOR members study are based on information—about how a molecule affects the body or about how well an health technology assessment process works—and this knowledge is a global public good, potentially benefitting 7 billion people on the planet.” ISPOR’s Board of Directors are elected by its global membership. The International Society for Pharmaco-economics and Outcomes Research (ISPOR) is a non-profit, international, educational and scientific organiza-tion that promotes health economics and outcomes research excellence to improve decision making for health globally.

WELCOME TO OUR NEW STUDENTS AND FELLOWS

INCOMING STUDENTS

Master of Science in Pharmacy Degrees

Sarah Baradaran, BS 2010, Baylor University; PharmD 2015, University of Washington, MS 2016 University of Washington Thesis: “The Identification, Characterization, and Costs of Ad-verse Outcomes associated with Systemic Colistin in the Man-agement of Severe MDR Gram Negative Infections” Chair: Beth Devine, PharmD, MBA, PhD

Catherine M. Lockhart, BFA and BS 1998, University of Idaho; BS 2004, PharmD 2013, University of Washington, MS 2016 University of Washington Thesis: “Value Assessment of Orphan Drugs and Treatments of Rare Diseases” Chair: Ryan Hansen, PharmD, PhD

Jean Malacan, PharmD 2015, Université Paris-Sud (France); EM 2015, ESSEC Business School (France); MS 2016 Universi-ty of Washington Thesis: “Cost-Effectiveness Analysis of Addition of Bevacizumab to a Standard Chemotherapy Doublet in Patients with Malignant Pleural Mesothelioma” Chair: Josh Carlson, PhD, MPH

Amy Tung, BA 2001, PharmD 2015, University of Washington; MS 2016 University of Washington Thesis: “Characterizing Healthcare Utilization, Direct Costs, and Comorbidities Associated with Interstitial Cystitis: A Retrospec-tive Claims Analysis” Chair: Beth Devine, PharmD, MBA, PhD

Doctor of Philosophy in Pharmacy Degrees

William J. Canestaro, AB 2006, Dartmouth College; MSc 2008, Oxford University (United Kingdom); PhD 2016, University of Washington Dissertation: “Publication Bias: Development and Assessment of Methods for Adjustment and Quantification of Impact” Chair: Josh Carlson, PhD, MPH

Amy Morgan Cizik, BA and BA 2001, University of Missouri, Kansas City; MPH 2004, University of Kansas; PhD 2016, Uni-versity of Washington Dissertation: “Variations in Surgeon Treatment Preferences and the Impact on the Cost-Utility of Surgery for Soft Tissue Sar-coma” Chair: Lou Garrison, Sr., PhD

Cara Lyn McDermott, BA 1999, Princeton University; PharmD 2011, MS 2012, University of Washington; PhD 2016, Universi-ty of Washington Dissertation: “The Impact of Pre-existing Depression on Patient Outcomes among Older Adults with Non-small Cell Lung Can-cer” Chair: Sean Sullivan, PhD

Marita Zimmermann, BS 2007, Carnegie Mellon University; MPH 2012, Brown University; PhD 2016, University of Wash-ington Dissertation: “Evaluation and Potential Cost-Effectiveness of Active Surveillance Pharmacovigilance for First-Line HAART in Namibia” Chair: Andy Stergachis, PhD

2016 Graduates 1st Row: Jean Malacan, MS; Amy Tung, MS; Sarah Baradaran, MS; Cara McDermott, PhD 2nd Row: Amy Cizik, PhD; Marita Zimmermann, PhD 3rd Row: Cate Lockhart, MS; William Canestaro, PhD

NEW ALUMNI

CLASS OF 2016

/ UNIVERSITY OF WASHINGTON SCHOOL OF PHARMACY

Shuxian Chen, MA; PhD Student Shuxian transferred to PORPP from the Uni-versity of Washington's Department of Eco-nomics, where she has been training in eco-nomic theory for a year. Before coming to UW, she earned her master’s degree in eco-nomics from Duke University in 2015, where she developed a strong interest in health economics. Her research interests include quantitative analysis of patients' and manu-

facturers' decision-making, and assessment of long-term healthcare services. She looks forward to joining PORPP and exploring the pharmaceutical industry from an economic per-spective.

Shalak Gunjal, MS; PhD Student Shalak joins PORPP from the Mayo Clinic’s Evidence-based Practice Center where he worked in generating evidence to develop clinical practice guidelines for federal agencies, professional societies, and patient organizations. After receiving his pharmacy degree in India, he worked in pharmaceutical marketing and then went on to earn his master’s degree in pharmaceutical outcomes from the Uni-

versity of Houston. He has worked in various academic, consult-ing and public health settings in the past, notably at the Center for the Evaluation of Value and Risk in Health at Tufts Medical Center, Precision Health Economics and the Bureau of Epidemi-ology at Houston Department of Health and Human Services. Shalak is interested in understanding the economic and policy implications of using personalized medicine in patient care along with studying access and utilization variations contributed by insurance coverage and reimbursement decisions in chronic diseases. Outside of research, he enjoys hiking in the National Parks and looks forward to getting his hands dirty in excavating geoducks and exploring the Pacific Northwest.

Erik Landaas, MPH; PhD Student Erik received his MPH degree from the Uni-versity of Washington and has been a lead-er with Washington State’s public health care purchasers. He managed Washing-ton’s Dossier Program - an evidence-based coverage decision process for evaluating new and emerging medical technologies. Erik has worked closely with Washington’s Health Technology Assessment (HTA) pro-gram and Washington’s Agency Medical

Directors Group (AMDG). As Washington State’s Manager for Healthcare Policy and Payment Methods, he was in charge of several complex healthcare delivery systems and brings exper-tise in medical rate setting, policy, outcomes, analytics and evi-dence-based practice. Erik also has local public health experi-ence in the prevention and surveillance of HIV, STD, Hepatitis and other communicable diseases; opioid dosing guidelines, overdose, treatment and detox; as well as behavioral health pro-grams. He is interested in pharmacoeconomics, medical epide-miology and cost-utility analysis; and plans to extend his re-search skills and abilities to take on more sophisticated studies in value based healthcare purchasing, health technology assess-ment, and clinical outcomes.


INCOMING STUDENTS

NEW ALUMNI

CLASS OF 2016

Harry Lee, PharmD; MS Student Harry will be continuing his education and training at the University of Washington, where he will be working towards earning a Master of Pharmaceutical Sciences degree in health economics and outcomes re-search. Prior to his postdoctoral training, he earned his PharmD from the University of Washington in June 2016, where he com-pleted a rigorous curriculum with a focus in managed care, decision modeling, health

economics and outcomes research. As a pharmacy student, Harry competed in the AMCP P&T Competition and placed na-tionally as a semifinalist, which affirmed his passion in HEOR. In his fourth year, he worked on a cost-effectiveness analysis of intensive LDL cholesterol reduction with PCSK9 Inhibitors as an adjunct to high-intensity statins for the prevention of major vas-cular events in patients with familial hypercholesterolemia and other high risk groups. Both projects were finalist poster presen-tations at the ISPOR 21st Annual International Meeting and the AMCP 28th Annual Meeting, and are currently being prepared for publication. Harry is excited to continue his education and training in PORPP to further advance his skill set in health eco-nomics and outcomes research.

Michael Serbin, PharmD, UW/Allergan Post-Doctoral Fellow 2016-2018 Michael received his PharmD degree from the University of Washington School of Pharmacy in 2016 and a BS in biomedical engineering from the University of South-ern California in 2011. At UWSOP he worked as a research assistant for Dr. Veenstra. Michael has interests in P&T decision-making, formulary development, and the use of economic modeling to do

so. He focused during his 4th year PharmD clerkships on formu-lary development and wrote P&T submissions at Premera Blue Cross, UW Medical Center, and Providence Health. Michael also competed in the AMCP P&T competition where his team won the local competition and placed as semifinalists nationally. This year Michael is excited to start working with PORPP faculty and the HEOR team at Allergan to improve his research and economic modeling abilities.

Sheila Shapouri, PharmD, UW/Allergan Post-Doctoral Fellow 2016-2018 Sheila joins the UW/Allergan fellowship after receiving her PharmD from the University of Washington in 2016. Prior to pharmacy school, she worked as a research associate at the Allen Institute for Brain Science gener-ating publicly available neuroscience and genetics resources now used by researchers worldwide. Although she has left the lab, her

interest in improving health outcomes at a patient population level through targeted research continues. During pharmacy school, Sheila completed clinical clerkships at the Food and Drug Administration (FDA), PATH, and the Centers for Disease Control and Prevention (CDC). There she engaged in the appli-cation of surveillance and outcomes data to guide healthcare decisions and policy at a national and global level. Sheila also participated in the AMCP P&T Competition where her team placed first locally and as semi-finalists nationally. Sheila is looking forward to the opportunity to work with the PORPP fac-ulty and Allergan team.

PORPP /

CURRENT GRADUATE STUDENTS AND FELLOWS

Certificate in Health Economics and Outcomes Research

The Certificate in Health Economics and Outcomes Re-search program is entering its 5th year. Launched at the start of the 2012-2013 academic year in conjunction with the UW Professional and Continuing Education program, this distance learning program is designed for professionals working in health care settings including payer organiza-tions, health insurance industry, government, the life scienc-es, pharmaceutical and biomedical industries, and for pro-fessionals working within Health Technology Assessment or reimbursement organizations. The program offers one course per academic quarter; Fall quarter: Principles of Health Economics, taught by Lou Garrison and Anirban Basu; Winter quarter: Economic Evaluation, taught by Dave Veenstra and Josh Carlson; Spring quarter: Practice of HTA in a Global Environment, taught by Sean Sullivan and Beth Devine. During the program, students learn the key econom-ic concepts and analytical tools of human economic behav-ior, explore the current state-of-the-art in the economic eval-uation of health care technologies, and are introduced to the principles and methods of HTA practice. Students work in groups throughout the program on a capstone project, which applies their learning to an assigned country. Student evalu-ations have remained positive over the years. Many of the students are international, a testament to the program’s global reach. Applications have routinely been 60+ since the first of the program. The 2016-2017 program is on target to reach similar numbers. The program now has an active LinkedIn alumni group. Courses are continually being updat-ed and revised to keep pace with changing technologies and economies. Revenues from the Certificate in Health Eco-nomics and Outcomes Research program support 1-2 PORPP teaching assistant positions each year.

Visit: http://www.pce.uw.edu/certificates/health-economics.html for additional information.

Lauren Strand, MS; PhD Student

Lauren comes to PORPP from the Uni-versity of Washington’s Department of Epidemiology. Recently, she has served as an analyst on a data harmo-nization effort in HIV with a main focus on mental health, medication adher-ence, and substance use domains. Relocating to Seattle from Boston in 2014, Lauren previously worked in Evidera’s Meta-Research group. Since then, her interest in pharmacoepidemi-

ology has grown. One of her recent projects investigated long-term statin use and longitudinal change in cardiac structure. She hopes to continue to look at unanticipated and/or rare drug effects, but she is also eager to learn more about pharmaceuti-cal policy and health economics. Importantly, she is excited to join the PORPP family.

Lucille Sun, PharmD, UW/Bayer Post-Doctoral Fellow 2016-2018

Lucille is a graduate from the University of California San Francisco (UCSF) School of Pharmacy. As a health eco-nomics intern at Genentech, she con-ducted retrospective database analyses in orphan diseases such as acromegaly and hemophilia A. She further took on a role in Genentech’s Global Pricing & Market Access group where she updat-ed and finalized the payer value mes-

sages and objection handler to support affiliate negotiations for Cotellic in metastatic melanoma. Lucille hopes to gain a deeper understanding of value frameworks and their influence on pric-ing and reimbursement strategies. Joining PORPP, she also looks forward to working with excellent faculty and building skills in health technology assessment, economic modeling, and real world evidence generation.


INCOMING STUDENTS


Graduate Certificate in Comparative

Effectiveness Research

Now in its 5th year, the UW Graduate Certificate in CER is the cornerstone of the UW Center of Excellence for CER Education, and is open to currently enrolled MS and PhD students to provide training in cutting edge CER research methods. Coursework consists of advanced methods in observational data analysis, decision sciences, preference assessment, network meta-analysis, and Bayesian statis-tics. A capstone project is also required. Originally spon-sored by the PhRMA Foundation, the UW CER Center of Excellence has supported 5 PhD students with dissertation stipends ($10,000 each), 3 students with one-year research assistantships, and an additional 3 students who have com-pleted the program without funding support. The Center will undergo its five year review by the UW Graduate School this fall. Lou Garrison, Beth Devine, and Anirban Basu lead the Certificate Program; all PORPP faculty contribute. Larry Kessler and Dave Grembowski contribute from Health Ser-vices. Penny Evans is the Program Administrator. Interested par-ties can visit: http://sop.washington.edu/porpp/certificate-programs/graduate-certificate-in-comparative-effectiveness-research.html for additional information.

UPDATE ON THE PORPP CERTIFICATE PROGRAMS

http://sop.washington.edu/porpp/certificate-programs/graduate-certificate-in-comparative-effectiveness-research.html



CURRENT GRADUATE STUDENTS AND FELLOWS

Blythe Adamson, MPH; PhD Student In her second year, Blythe most enjoyed exploring and developing static and dynam-ic transmission models for infectious diseas-es like HIV and influenza. She successfully finished core coursework, passed the pre-liminary exams, and had her dissertation short proposal approved for development under the mentorship of Dr. Lou Garrison. Blythe collaborated with UW Bioengineering

to develop a cloud connected rapid influenza diagnostic test with improved performance, a project awarded a technology prize and presented at ISPOR. She also gained experience providing health economics support to three HIV research groups at Fred Hutch who are studying financial incentives in the US, testing in Peru, and vaccines in South Africa. This sum-mer Blythe is working at the Institute for Disease Modeling at Intellectual Ventures coding economic indicators into an HIV microsimulation model. The University of Washington recog-nized Blythe’s enthusiasm this spring by including her in the Husky 100, an award for passionate students making a differ-ence on campus, in their community, and for the future.

Sarah Baradaran, PharmD, MS UW/Allergan Post-Doctoral Fellow 2015-2017 Sarah has finished the first year of her fel-lowship and has begun her second year, on-site at Allergan in Irvine, CA. Over the past year she has been working on her master’s thesis: “The identification and characteriza-tion of acute kidney injury (AKI) associated with systemic colistin in the management of severe gram negative infections.” She is

excited to continue her research in this area in the upcoming year. Additionally, she presented a poster on phar-macogenomics at the ISPOR 21st Annual International Meeting in collaboration with her colleagues at UW.

Mark Bounthavong, PharmD, MS; PhD Student Mark is a third-year PhD student who is working at the Department of Veterans Af-fairs (VA) in the National Academic Detail-ing Program Office (ADPO). Mark's disser-tation will evaluate the impact of the ADPO on naloxone prescribing at the VA and ex-plore provider perception of academic de-tailing. Mark's research interests also in-clude health technology assessment, meta-

analysis, and large database analysis. Mark presented a poster at the 21st Annual ISPOR Conference titled: “Economic Evalu-ation of In-home Telehealth Compared to In-person Treatment Delivery for Managing Depression.” Mark recently published a paper with fellow classmate, Meng Li, and a PORPP alum, Jon-athan H. Watanabe, entitled "An evaluation of health care ex-penditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013" in Research in Social and Administrative Pharmacy.

Elizabeth Brouwer, MPH; PhD Student Elizabeth joined PORPP from University of Washington’s Department of Global Health, where she worked for over two years as a Health Economics Analyst on Disease Con-trol Priorities, summarizing and synthesiz-ing economic evidence for health policy in low-resource settings. Before coming to Seattle, Elizabeth received her Master of Public Health in Health Economics at the University of Michigan (’13) while working

with health service utilization data for tuberculosis patients in South Africa. During her 2nd year in the program, Elizabeth will work with Professor Josh Carlson as an RA on the ICER grant. Her other research interests include value-based health policy and management of non-communicable diseases in low-resource settings.

William Canestaro, MS; PhD Candidate Will is finishing his fourth year of the PhD program and is scheduled to defend in the Fall of 2016. The focus of his research is developing methods to estimate societal economic loss from publication bias. Will has spent the past year serving as the re-search assistant for the federally-funded PriMER study, for which Drs. Carlson and Veenstra are both principal investigators. Will's doctoral work was supported by com-

petitive grants from the PhRMA Foundation and American Foundation for Pharmaceutical Education. Will has begun a full-time position with the Washington Research Foundation as a Manager of Strategic Investments. In this role Will is evaluating equity investments in early stage healthcare companies and research grants to promising technologies from Washington-based research institutions.

Devender Dhanda, BSPharm, MS; PhD Student Devender will be entering his fourth year of the PhD program in PORPP. During his third year, Devender completed his course-work requirements and worked with Dr. Dave Veenstra on the Personalized Medi-cine Economics Research (PRiMER) grant. Devender worked on evidence comparison between the pharmacogenomics-based and clinical decisions based on drug-drug

interactions by running value of information analysis (VOI) of the warfarin amiodarone drug-drug interaction and phar-macogenomics-based warfarin dosing. Devender presented his work as poster and podium presentations at 37th Annual Meet-ing of Society for Medical Decision Making (St. Louis, MO) and 2016 Canadian Health Technology Assessment Symposium (Ottawa, Canada). He also finalized his dissertation topic selec-tion and submitted a short proposal on “Innovation and Uncer-tainty in Oncology Precision Medicine” for his PhD dissertation. Devender was awarded the prestigious Magnuson Scholarship for the 2016-2017 academic year. During his fourth year, Devender plans on completing his gen-

eral exam by the end of fall quarter and embarking on his dis-

sertation research.


INCOMING STUDENTS

PORPP /

CURRENT GRADUATE STUDENTS AND FELLOWS, CONT.

Horacio Duarte, MD; MS Student Horacio is entering his 2nd year as a mas-ter’s degree student in PORPP and 3rd year as a pediatric infectious diseases fel-low at Seattle Children’s Hospital/University of Washington. Prior to his in-fectious diseases fellowship, Horacio earned a B.A. in biological anthropology from Harvard College, an M.D. from the University of Texas Medical School at Hou-

ston, and he completed his pediatrics residency at Seattle Chil-dren’s Hospital. He is interested in economic evaluation of global health programs, with a special interest in HIV and child health, and he is currently studying the cost-effectiveness of HIV drug resistance testing in Kenya. His research is funded by the Pediatric Scientist Development Program K12 Award.

Simrun “Simi” Grewal, MHS; PhD Student During her second year in the PhD program, Simi enjoyed working with Dr. Josh Carlson and colleagues on the Personalized Medi-cine Economics Research (PriMER) project. As an RA on PriMER, she has assisted on developing discrete choice experiment sur-veys to explore preferences for genetic test-ing from different stakeholder perspectives. The team’s work has been accepted for a

poster presentation at the Society for Medical Decision Making (SMDM) conference in October. Additionally, Simi has provid-ed research support to two key initiatives led by the Internation-al Society for Pharmacoeconomics and Outcomes Research (ISPOR) on Vaccine Economic Evaluation and Value Assess-ment Frameworks. Entering her third year, Simi is excited to continue learning in her research roles while exploring the next stages of her dissertation proposal.

Laura Hart, PharmD; MS Student Laura will be entering her second year in the PORPP M.S. degree program. She is con-currently completing a two-year combined PGY2 residency and fellowship in geriatric pharmacy with the UW School of Pharmacy. She has been awarded the 2016-2017 UW Retirement Association Graduate Student Fellowship in Aging. This coming year, she will complete her master's thesis under the guidance of her faculty mentors Zach Mar-

cum and Shelly Gray. Her thesis is examining the association between central nervous system-active medications and falls in older adults with dementia.

Nathaniel Hendrix, PharmD; PhD Student Nathaniel is entering the second year of his PhD program. During the past year, he has completed a portion of his coursework while also working for the Seattle-based non-profit PATH. He also served as a consultant for ISPOR's vaccine task force and as a re-search assistant for Dr David Veenstra's psoriasis modelling project for the Institute for Clinical and Economic Review. In the

coming year, he will finish his coursework and begin a project with Dr Beth Devine on the cost-effectiveness of phar-macogenomic clinical decision support.

Meng Li, ScM; PhD Student Meng is entering her fourth year in the PhD program. She has started working on her dissertation, which is examining the real options value of life and innovation. During the past year, she has been working with faculty on a number of projects, including establishing a framework for examining the value of information of heart failure clinical trials, validating a new instrument that measures the psychological impact associ-

ated with genetic testing, examining the utilization patterns of opioid in Washington State, and, examining the acceptability and performance of using visual inspection for cervical cancer screening in resource-limited settings.

Solomon Lubinga, BS Pharm; PhD Candidate Solomon is entering the fifth year of the PhD program in PORPP. In the past year, he continued his work with Drs. Andy Stergachis and Joseph Babigumira in the Global Medicines Program to support a hu-man resources intervention to strengthen the supply chain of essential medicines in Malawi. He is preparing two manuscripts from this work. He submitted a manuscript

reporting his work with Dr. Brian Custer (Blood Systems Re-search Institute) to estimate the cost-effectiveness and budget impact of Methylene Blue Treated Plasma compared to the Quarantine Plasma for pathogen reduction in Spain. He passed his general examinations and is working on the first aim of his dissertation. This is a qualitative research piece that will form the foundations of a choice experiment that explores the prefer-ences and behavioral psychological factors affecting individual decisions about medical male circumcision for HIV prevention.

Jean Malacan, PharmD, ECCM, MS UW/Bayer Post-Doctoral Fellow 2015-2017 Jean received his PharmD degree from the Paris Sud University in 2015, completing the same year an executive advanced master in strategy & management of health industries at the ESSEC business school. Jean has completed the first year of the Bayer Post-Doctoral Fellowship and has received a mas-ter of science in pharmaceutical outcomes research and policy, focusing on economic

evaluation, epidemiology and statistics, and applying it to cur-rent mesothelioma treatments in his thesis. Starting his second year, he is excited to work with the US HEOR Bayer team in Whippany, New Jersey, and receive real-world training in a major pharmaceutical company recognized for its commitment to innovation.


STUDENT’S ENTERPRISE YIELDS 3 “essentially paid for” DEGREES By Sarah Guthrie


Blythe Adamson, PORPP PhD student shares tips for self-funding success

Blythe Adamson whiteboards a problem in health economics research with colleagues Nathaniel Hen-drix, left, and Wei-Jhih Wang.

Alex Levine

PORPP /

You would think three degrees from the University of Washing-ton would take an enormous financial toll, but School of Phar-macy grad student Blythe Adamson, one of the UW’s Husky 100, has been energetic and enterprising about finding funding. “I will graduate with all three of my degrees essentially paid for through a variety of public and private support,” she shared.

Her secret: She applies for everything. “It’s a numbers game of sorts,” she figures, influenced by a colleague’s suggestion that if the average grant or fellowship acceptance rate is 13 per-cent, applying for at least 10 opportunities should land at least one. (The colleague had applied for 10 scholarships and re-ceived two.)

Over the past 18 months, Adamson applied for 20 scholar-ships. She initially received nine rejections in a row. “It was disheartening, but it gave me a thick skin about my research and writing.” Finally, the tide turned and she received five awards.

The benefits have built her confidence as well as her pocket.

“Filling out applications over and over prepares me for a future of grant writing,” she said. And in reapplying for one of the nine she didn’t win last year, she said, “I can see improvements in the quality of my writing and, in particular, how I describe my research.”

As an undergrad studying microbiology, Adamson was a two-time Mary Gates Research Scholar for her work in an HIV lab. She earned a master’s degree in public health (epidemiology) with financial support from Fred Hutch.

In 2014, she decided to pursue a doctorate in pharmacy to study with one of the world’s leading pharmaceutical econo-mists.

“With most American HIV researchers [being] at the age of re-tirement, I knew it was time for me to return to UW for a Ph.D. to gain the tools to carry the foundational HIV research forward and one day have an AIDS-free generation,” she said.

To find funding, Adamson subscribes to listservs and searches broadly among prospective sources, such as organizations that support women in science, HIV and AIDS research, and eco-nomics research. Public funds often come with restrictions, she has found, whereas private grants and fellowships afford more flexibility in paying for school fees, research and conference travel.

A pre-doctoral fellowship from the Agency for Healthcare Re-search and Quality funded two years of tuition and provided a stipend; this gave her more time to hunt for other opportunities – time that might’ve instead been working part-time in a class or lab.

It took Adamson a while to recognize and appreciate the relative anonymity of the application process.

“At the beginning, I felt very self-conscious and vulnerable writ-ing my personal statement and research aims, but after 20 ap-plications I feel much more comfortable with myself and what I feel passionate about. I like to remind myself that, in most cas-es, I won’t ever meet the people reading my application,” she said.

“And I hate the thought of leaving free money on the table.”

STUDENT’S ENTERPRISE YIELDS 3 “essentially paid for” DEGREES By Sarah Guthrie

http://expd.washington.edu/mge/apply/research/index.htm


Cara McDermott, PharmD, MS, PhD Cara completed her PhD and the Compara-tive Effectiveness Research certificate in June 2016. She is a T32 postdoctoral fellow with the Cambia Palliative Care Center of Excellence at the UW School of Medicine, where she is evaluating end-of-life care for older adults with cancer. Cara is grateful for the support and mentorship of the PORPP faculty.

Vanessa Shih, PharmD, MS UW/Allergan Fellow, 2014-2016 Vanessa has completed the second year of her fellowship, working under the mentorship of Joanna Campbell and Hitesh Chandwani, in the Global Health Economics and Out-comes Research team at Allergan. She was fortunate to work on a variety of projects in the Eye Care therapeutic area including claims analyses and electronic medical rec-ord analyses. Additionally, she presented a

poster at the Annual Meeting of the Association for Research in Vision and Ophthalmology on “The Association between Onset of Self-reported Vision Impairment and Nursing Home Resi-dence in an Older US Population.” She is excited to continue on at Allergan supporting the Retina products.

Kangho Suh, PharmD, MS; PhD Student Kangho is entering his third year in the PhD program in PORPP. In the past year he was the RA for a project funded by the Corporate Advisory Board assessing the value of cures. In the summer he worked as a RA with Carrie Bennette on identifying possible factors that are associated with a cancer site’s participation in clinical trials. He also hopes to create and develop a dissertation idea by the end of the summer. In the up-

coming year he will work as a RA with Anirban Basu and Justin Robertson using instrumental variable methods to estimate comparative effectiveness of alternative bariatric surgery proto-cols.

Amy Tung, PharmD, MS UW/Allergan Post-Doctoral Fellow 2015-2017 Amy received her PharmD degree from the University of Washington (UW) in 2015. Her interest in health economics and outcomes research (HEOR) grew from the desire to blend her background working in the tech industry as a market researcher with her interest in pharmaceutical outcomes and health policy. Her passion for HEOR contin-ued to grow after taking various pharmaco-

economics and managed care electives in pharmacy school. She further developed an appreciation for the field serving as president of UW’s Academy of Managed Care Pharmacy chap-ter, as well as through her experience writing dossiers for phar-maceutical companies.

She spent the past year building a strong foundation for becom-ing an effective health economics and outcomes researcher through coursework in biostatistics, epidemiology, economic evaluations, and patient-reported outcomes. For her thesis project, she conducted a retrospective claims-based analysis to assess the burden of interstitial cystitis in the US using a nationally representative dataset. Amy is excited to move to Orange County, and start the second year of her fel-lowship working in urology at Allergan.

Elisabeth Vodicka, MPH; PhD Candidate Elisabeth is entering her 4th year in PORPP as a PhD Candidate having passed her gen-eral exam in June. Last year, Elisabeth worked as a research assistant on a Gates-funded economic evaluation of portable ul-trasound in low-income countries with Drs. Brian Bresnahan, Joseph Babigumira, and Lou Garrison. She continued to collaborate with Dr. Andy Stergachis and researchers at Universidad Peruana Cayetano Heredia in

Lima, Peru to assess the potential for private pharmacies to offer point-of-care screening and disease management services for hypertension and other non-communicable diseases. Her dissertation will focus on the integration of cervical cancer screening into existing healthcare services in Kenya and Ugan-da. This summer, Elisabeth completed a health economics in-ternship in the Reproductive Health division at PATH in Seattle.

Wei-Jhih Wang, MS; PhD Student Wei-Jhih is entering the second year in PORPP, and completed the required course-work. Last year, she worked with Dr. Ryan Hansen and Dr. Laurie Gold on the projects that involved literature reviews for multiple sclerosis and infantile spasm, and used Mar-ketScan data for infantile spasm. Wei-Jhih also worked as a RA with Dr. Beth Devine and analyzed data for the project of phar-macogenomics. Her independent study is

working with Dr. Anirban Basu and Dr. Steve White on the topic of seizure and stroke, and she will also explore the potential research topics. This summer, she is working with Dr. Carrie Bennette and doing data management for several public data sources to explore the relationship between characteristics of geographic area and clinical trials.

Marita Zimmermann, MPH, PhD Marita Zimmermann is working on a UW project team with the Institute for Clinical and Economic Review. Her first project with this group will be examining the cost-effectiveness of various therapies for re-lapse-remitting multiple sclerosis. In Febru-ary 2016, Marita completed her dissertation and gained her PhD in PORPP. Marita’s dissertation focused on the feasibility of a national active surveillance system for HIV medication in Namibia. This work resulted

in two recent manuscripts. In addition, Marita continues to work on the cost-effectiveness of cervical cancer screening in Kenya, and other global health projects.

2016 PORPP PRIZE RECIPIENTS


2016 PORPP GRADUATE STUDENTS AT ISPOR

The Louis Garrison Sr. and Marilyn Garrison Endowed Prize in Health Policy and Economics is intended to rec-ognize annually an outstanding research paper in the ar-ea of health policy and economics. PORPP Professor Louis Garrison, Jr, and his wife, Fran established this fund in 2008 in fond memory of his parents Louis P. Garrison, Sr. and Marilyn J. Garrison, who were great believers in the value of education and science. This year the prize was shared by Will Canestaro for his paper titled: “Implications of Employer Coverage of Con-traception: Cost-Effectiveness of Contraception Under an Employer Mandate” and Elisabeth Vodicka for her paper titled: “Costs of Cervical Cancer Screening Integrated into an HIV-Clinic in Kenya”. Both received a $500 monetary award.

2016 PORPP PRIZE RECIPIENTS

PORPP /

2016 PORPP GRADUATE STUDENTS AT ISPOR

PORPP LEADERSHIP UPDATES


The 3-quarter certificate program in Biomedical Reg-ulatory Affairs was developed at the request of local industry and launched in September 1998. Its core curriculum seeks to develop an understanding of reg-ulatory process for biologics, drugs and medical de-vices; a Clinical Trials Certificate followed in 2000. Both programs have enjoyed generous support from industry, the US Food and Drug Administration, and colleagues in the School of Law and the College of Engineering. UW Professional & Continuing Educa-tion has been an invaluable partner. Through spring 2016, 340 students have completed the Biomedical Regulatory Affairs certificate and 400 have completed the Clinical Trials certificate. Largely through student interest, a part-time Biomedi-cal Regulatory Affairs Master of Science (BRAMS) Degree program launched in 2008.

BIOMEDICAL REGULATORY AFFAIRS PROGRAM

FACULTY MILESTONES Professor Louis Garrison, Jr. Retires

By Sarah Guthrie

Dave Veenstra Associate Director, PORPP

Beth Devine Director, Graduate Programs

Josh Carlson Associate Director Graduate Programs

Sean stepping in to his Deanship, Anirban being ap-pointed the new Director of PORPP, and Lou becom-ing an Emeritus Professor, has opened up additional leadership opportunities for PORPP faculty. Dave Veenstra has been promoted from Director of PORPP Graduate Programs to Associate Director of PORPP, Beth Devine has been appointed as Director

of PORPP Graduate Programs, and Josh Carlson has assumed the role of Associate Director of Grad-uate Programs. All three faculty members look for-ward to furthering an already excellent leadership track record, and bring energy and ideas to their new roles. Congratulations to all!

The BRAMS advisory committee mandated that the curriculum stress communication skills and include a practicum. The current curriculum includes the cours-es of both certificate series: a two-course technical writing series; as well as courses in international reg-ulatory affairs, regulatory data essentials and analy-sis, medical risk analysis and management, regulato-ry affairs skills, and a 9-credit practicum. The 100

th

BRAMS student graduated in May. Again through student interest, we are currently seeking approval for a full-time, applied program. Students will enroll in both the core BRAMS course series, as well as a defined applied course series. Proposed series include: epidemiology, global health, health economics, medical biometry, and nutrition. We anticipate accepting up to 5 students per year, starting in Autumn 2017.

UWSOP Dean Sean D. Sulli-van announced Dr. Lou Garri-son’s retirement from the UW School of Pharmacy’s Pharma-ceutical Outcomes and Re-search Policy Program (PORPP) effective July 1, 2016. “Lou has been a pivotal member of the PORPP faculty and will continue to be a world-

class thought leader in health economics as Presi-dent of the International Society for Pharmacoeco-nomics Outcomes and Research (ISPOR). Lou is an extraordinary teacher, mentor, colleague and economist and we are so grateful for his years of service to the UW. He’s been key to the growth of the program and has mentored hundreds of preemi-nent students over his years on our faculty,” said Dean Sullivan. Lou came to UW in 2004 with a joint appointment as Associate Director and Professor in PORPP in the Department of Pharmacy and Adjunct Professor in the Departments of Global Health and Health Ser-vices in the School of Public Health. In 2013, he completed a sabbatical as Visiting Senior Research Fellow at the Office of Health Economics in London. In 2014, he graciously served as Interim Director of PORPP while a national search was run to fill the post.

In the 12 years before joining UW, he worked as an economist in the pharmaceutical industry. From 2002 to 2004, he was vice president and head of health economics and strategic pricing at Roche Pharmaceuticals in Basel, Switzerland and oversaw the development of the economic and pricing strate-gies, and research plans for all Roche compounds. Prior to this, he was director of the Project HOPE Center for Health Affairs, where he worked on a wide variety of health policy issues, including stud-ies of healthcare reform in the U.S. and overseas. Before this, he worked at the Battelle Human Affairs Research Centers in Seattle, where he carried out studies of the adequacy of physician manpower supply and the cost-effectiveness of kidney and heart transplantation.

BIOMEDICAL REGULATORY AFFAIRS PROGRAM

FACULTY MILESTONES Professor Louis Garrison, Jr. Retires

By Sarah Guthrie

PORPP /

His research interests include national and interna-tional health policy issues related to phar-macogenomics and personalized medicine, regula-tory benefit-risk analysis, insurance, pricing, reim-bursement, and risk-sharing agreements, as well as the economic evaluation of pharmaceuticals, diag-nostics, devices, surgical procedures, and vac-cines, particularly as related to organ transplanta-tion, renal disease, influenza, measles, obesity, and cancer. Lou’s deep commitment to the UW and our stu-dents is shown through two funds he and his family have created to support a leading-edge student ex-perience: Pharmaceutical Outcomes Research and Policy Program (PORPP) Endowed Prize in Health Policy and Economics and the newly es-tablished Garrison Family Fund for Global Health Economics Education. The Prize in Health Policy and Economics provides financial assistance to in-spire PORPP graduates to study and excel in the fields of health policy and economics. To ensure the future of global health economics education, the Garrison Family Fund supports a wide range of global health education activities in the UW School of Pharmacy including: student and faculty travel for global health economics education, workshops and trainings. We thank Lou for his dedicated service and in wish-ing him the best in his next evolution as a leader in health care.

Lou with PhD student Devender Dhanda at Husky Stadium, 2015 CAB.

http://www.ispor.org

http://www.ispor.org

https://www.washington.edu/giving/make-a-gift/?page=make&code=GARFOP

https://www.washington.edu/giving/make-a-gift/?page=make&code=GARFOP

https://www.washington.edu/giving/make-a-gift/?page=make&code=PORPOP

https://www.washington.edu/giving/make-a-gift/?page=make&code=PORPOP

PORPP Endowed Prize Recipient

RESEARCH HIGHLIGHTS

After nearly two and a half years of deliberations (and over five years of planning), the Second Pan-el on Cost-effectiveness in Health and Medicine has finalized their recommendation for the practice of medical cost-effectiveness analysis. Anirban Basu contributed several chapters to the Panel

report, which is due to come out on December 7, 2016 at a 1-day conference at the National Academies of Sciences in Washington DC. A summary of recommendations is also forth-coming in the Journal of the American Medical Association at the same time.

In May 2016, Carrie Bennette and co-authors Sean Sullivan and Scott Ramsey published a paper in Health Affairs that helps illuminate the complexity of anticancer drug pricing. They found several market forces that underlie chang-es in the prices of oral chemotherapy in the years after launch: prices rose nearly 10% with each

supplemental indication approved by the FDA and declined 2-3% with the introduction of a competitor. Carrie is currently evaluating how Medicare Part D impacted pharmaceutical inno-vation and recently began a collaboration with Peter Bach from Memorial Sloan Kettering Cancer Center to study pricing trends of intravenous chemotherapy agents.

The University of Washington School of Pharmacy (UWSOP) and the Institute for Clinical and Economic Review (ICER) have formed a partnership to leverage UWSOP’s expertise in eco-nomic modeling of pharmaceutical interventions to support ICER’s growing body of work in new drug assessments. Josh Carlson is leading the overall endeavor with many PORPP faculty leading different projects within it. To date we have completed an economic model evaluating newer drugs devel-oped to treat multiple myeloma. The UWSOP team is current-ly evaluating treatments for psoriasis, multiple sclerosis, and advanced non-small cell lung cancer for inclusion in future ICER reports.

The Pharmaceutical Outcomes Re-search and Policy Program has part-nered with both the Patient Cen-tered Outcomes Research Institute and also pharmaceutical manufacturers to explore the safety of prescription opi-oids. Ryan Hansen and his study team

have completed evaluations of policy interventions within health care systems and also new technologies aimed at stem-ming the tide of the opioid abuse epidemic. These projects have included real world outcome evaluations of the impact of reducing opioid doses among long-term opioid users in collaboration with Dr. Michael Von Korff at Group Health Research Institute, and also alternative treatment strategies for acute pain within hospitals and emergency departments. Drs. Hansen and Marcum are also actively collaborat-ing with Drs. Jeffrey Jarvik and Janna Friedly to better under-stand the utilization of opioids among people with back pain as well as methods work in characterizing adherence

to prescription opioids. Their research is informing future poli-cies and interventions within both health care systems and at the Federal level.

Investigators in PORPP are pursuing innovative methods and policy evaluation in Precision Medicine (PM). Dave Veenstra, Josh Carlson, and Anirban Basu have developed an econom-ic framework for assessing the value of PM technologies, quan-tified evidence thresholds for PM implementation, and are col-lecting patient, provider, and payer preferences for PM to guide the development of a PM diffusion model. These activities are part of an NIH funded grant, Personalized Medicine Economics Research (PriMER). Separately, Beth Devine and Dave Veenstra recently designed an RCT to assess a family commu-nication tool for genomics, in collaboration with multiple investi-gators across UW. This study proposal was led by Gail Jarvik, MD, PhD, in the Division of Medical Genetics, and along with other ongoing work in clinical genomics at UW places PORPP in a leading position in the development and evaluation of novel PM technologies and policies.

Beth Devine and John Gore are the UW Assistant Directors and site principal investigators of the Pacific Northwest Evi-dence-based Practice Center (EPC) and, along with Paul Krae-gel, UW EPC Program Manager, coordinate EPC projects across the three partner institutions: Oregon Health & Science University, the University of Washington CHASE Alliance, and Spectrum Research (Tacoma, WA). The UW joined the EPC program in 2013, and, to date has participated in twelve pro-jects ranging in scope from imaging for hepatocellular cancer to medication-assisted treatment for opioid use disorder. One cur-rently pending application proposes to synthesize the evidence for the use of telehealth modalities for acute and chronic consul-tation. This proposal includes a plan to estimate the cost-effectiveness of these telehealth interventions, a particular strength in PORPP. Several PORPP faculty have led and par-ticipated in these projects. In addition to Beth Devine and John Gore, these include Josh Carlson, Laurie Gold, Ryan Han-sen, Scott Ramsey, Sean Sullivan, and numerous colleagues from the UW Schools of Medicine and Public Health.

Biomarker-guided individualized deci-sion-making is an active area of re-search at PORPP. Aasthaa Bansal and Anirban Basu are using statistical modeling and decision theory to devel-op methods for the optimal timing of biomarker collection in settings of long-

term patient follow-up. These methods are motivated by Aasthaa Bansal’s research on optimal monitoring strategies for treatment sequencing in chronic myeloid leukemia, as part of a health outcomes research starter grant from the PhRMA Foun-dation. The goal of this project is to use existing clinical trials data to determine how to best use patient molecular response history to predict outcomes and guide treatment decisions over time. Aasthaa Bansal is also working with PORPP affiliate fac-ulty Lotte Steuten on statistical methods for developing cost-effective biomarker combinations for disease diagnosis and prognosis.


PORPP Faculty & Students Strengthening Pharmaceutical Systems in Developing Countries

By Andy Stergachis, PhD

RESEARCH HIGHLIGHTS

PORPP /

PORPP Faculty & Students Strengthening Pharmaceutical Systems in Developing Countries

By Andy Stergachis, PhD

ance pharmacovigilance was projected to be highly cost-effective to improve treatment for HIV in Namibia. Findings were reported in Drug Safety and a complimentary study was published in Pharmacoepidemiology and Drug Safety.

In 2015, we completed one of the world’s largest studies on the safety of medicines used to treat malaria in pregnant women in sub-Saharan Afri-ca, with an emphasis on the safety of artemisinin combination therapies (ACTs) in early pregnancy. Funded by the Bill & Melinda Gates Foundation, Andy Stergachis was principal investigator of this prospective cohort study of over 2,800 pregnant women, conducted with partner institutions in Burkina Faso, Mozambique, Kenya, in conjunc-tion with the Liverpool School of Tropical Medi-cine through the Malaria in Pregnancy Consorti-um. Findings were presented to a World Health Organization Evidence Review Group (WHO-ERG) in July 2015, who recommended that treat-ment of clinical uncomplicated malaria episodes in women in the first trimester of pregnancy should be updated to include first-line ACTs as a treatment option. This recommendation then went to the WHO Malaria Policy Advisory Com-mittee who recommended that this new data on miscarriage and congenital malformations follow-ing exposure to artemisinin derivatives in the first trimester of pregnancy should support the update of the WHO Guidelines for the treatment of malar-ia, following the process established by WHO. Results were reported at the ASTMH 2015 annual meeting and initial publications have appeared in Malaria Journal, BMJ Open, and Reproductive Health.

In addition to these three examples, over the past year PORPP faculty and/or graduate students have engaged in understanding how to integrate public health programs into pharmacies and drug shops in Peru to improve care for patients with hypertension (Elisabeth Vodicka); con-ducted trainings in pharmacoeconomics and health tech-nology assessment in Uganda and Kenya (Joseph Babi-gumira and Lou Garrison); and completed a study of 25 pharmaceutical companies’ and non-governmental or-ganization’s past, present, and planned evaluations of their medical donation programs, with an emphasis on outcomes and impact, funded by the Partnership for Quality Medical Donations (Meng Li, Alisa Jenny, and Andy Stergachis).

PORPP faculty and graduate students are helping im-prove access to medicines in developing countries. De-spite some progress towards achieving the Millennium Development Goal access to medicines, the availability of essential medicines remains low in developing coun-tries. Compounding this problem is concerns with the quality of medicines, weak regulatory and distribution systems for medicines, and an insufficient supply of and access to pharmacy workers. Here are three examples of how our faculty and graduate students are addressing many of these challenges in developing countries through the PORPP-affiliated Global Medicines Program.

The sub-Saharan African country of Malawi re-flects many of these challenges. Many health centers suffer from frequent shortages of medi-cines and other supplies, largely attributable to poor supply chain performance. Joseph Babi-gumira, Andy Stergachis, Solomon Lubinga, and Alisa Jenny have been involved in a three-year program designed to improve health system ca-pacity through training and deploying pharmacy assistants to support primary health care in Mala-wi. This activity is a partnership between Villag-eReach, the Barr Foundation, the Malawi Ministry of Health, the Malawi College of Health Sciences, and the University of Washington.

The impact evaluation protocol was published in Implementation Science.

In the country of Namibia, Marita Zimmermann led a project evaluating the cost-effectiveness of a national active surveillance pharmacovigilance system for highly active antiretroviral therapy (HAART) compared with the existing spontaneous reporting system in that country. This activity, supported by the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program funded by the US Agency for International Devel-opment (USAID), concluded that active surveill-

POST-DOCTORAL FELLOWS

Souvik Banerjee, PhD Souvik has completed his second year as the Pfizer Senior Post-Doctoral Fellow at PORPP. He has been involved with two studies looking at the patterns in the use of prescription opioids, par-ticularly those with an extended-release formulation for the treatment of chronic pain for children. He presented two posters, based on this work, at the 35

th American Pain Society Annual Meet-

ing. Souvik was also a discussant for the paper, “The costs of crime during and after publicly-funded treatment for opioid use disorders: a population-level study for the state of California” at the 6

th Vancouver Health Economics Methodology (VanHEM) meeting. Moreover, he has a keen

interest in modeling the impact of different health interventions and policies on varied outcomes using alternative causal frameworks. His recent work with Anirban Basu, comparing the tradition-al instrumental variables approach and the latent factor model was presented at the 6th Biennial Conference of the American Society of Health Economists (ASHEcon). In the policy realm, he is working with Ryan Hansen and Anirban Basu on a project to assess the impact of marijuana

laws in Washington State and in Colorado on medical costs, opioid related outcomes and healthcare utilization. He has recently accepted a position as Research Assistant Professor at Boston University in the Section of General Internal Medicine, School of Medicine. He will begin his new position in October of this year.

Alice Ellyson, PhD Alice will begin the Pfizer postdoctoral fellowship after receiving a PhD in Economics from Flori-da State University in April of 2016. In her dissertation, she investigated the effect of medical malpractice liability reforms on the practice of defensive medicine among family medicine physi-cians funded by a $35,000 grant from the Gus A. Stavros Center. Her research included a study of physician decision-making using a dataset of 28,277 family medicine physicians over 16 years and various discrete choice models. In 2014, Alice had the honor of attending the 5th Lindau Meeting on Economic Sciences with Nobel prize winning economists sponsored by the National Science Foundation in Lindau, Germany. As a postdoctoral fellow, she will be mentored by Lou Garrison and Anirban Basu at the University of Washington and Cristina Masseria at Pfizer.

Jevay Grooms, PhD Jevay recently completed a PhD in Economics at the University of Florida. Her broad research interests lie in factors which impede early detection and the effective healthcare delivery in un-der-served communities. Her dissertation focused on the health implications of the World Trade Organization's Agreement on Trade Related Aspects of Intellectual Property Rights and less-developed members access to pharmaceutical drugs. She has two papers in progress; Early Intervention for Children Who are Deaf or Hard of Hear-ing: The States that Have it Right, and, Health Education in Primary Schools or Learned at Home; Estimating the Effects on Health Outcomes into Adulthood.

Kai Yeung, PharmD, PhD

Kai Yeung PharmD, PhD, just completed his PhD in PORPP September 2016. For this year, he is post-doctoral fellow at PORPP working on a project supported by the UW Program in Policy Research for Health Technologies entitled, “Paying for Cures and Other High-Cost, Break-through Treatments: Value, Affordability, Financing, and Policy Challenges”. He has conducted interviews with 20 healthcare payers and manufacturers on the topic of coverage and pricing for high cost curative treatments. Following this, he surveyed over 100 audience members at the annual meeting of the Academy of Managed Care Pharmacy during an educational session on policy options to pay for innovative curative treatments. Kai was recognized for the “best student paper award” for his dissertation work at the Vancouver Health Economics Methodology (Van-HEM) Meeting. He was also recognized for runner up for the “best paper of the year award”. This Fall, Kai will be starting a new position at Group Health Research Institute as an assistant scientist.

POST-DOCTORAL FELLOWS, cont.


JUNIOR FACULTY

POST-DOCTORAL FELLOWS

Melissa Rosen, PhD Melissa received her PhD in Social Policy from Brandeis University in 2016. Prior to completing her doctorate, Melissa worked as an analyst for the U.S. Department of Health and Human Ser-vices. In addition, she holds Master of Public Health and Master of Science in Nutrition degrees from Tufts University. Her research has focused on Medicare Part D insurance plan switching behavior and associated health and spending outcomes among individuals with chronic mental and physical illness. Additional research interests include psychotropic medication access and adherence, policies and programs that affect Medicare-Medicaid dually eligible beneficiaries, and impacts of drug plan formularies and utilization controls on medication utilization, cost and health-related outcomes. As part of her fellowship, she will work on NIH funded research for Dr. Anirban Basu and Dr. Nor-ma Coe including, their “Value of Information Methods for NHLBI Trials” and “Current and Future Costs of Alzheimer’s and Dementia Care” projects. Melissa is excited to join PORPP to further develop her health economics and outcomes research skills.

Marita Zimmermann, PhD Marita Zimmermann is working on a UW project team with the Institute for Clinical and Economic Review. Her first project with this group will be examining the cost-effectiveness of various thera-pies for relapse-remitting multiple sclerosis. In February 2016, Marita completed her dissertation and gained her PhD in PORPP. Marita’s dissertation focused on the feasibility of a nation-al active surveillance system for HIV medication in Namibia. This work resulted in two recent manuscripts. In addition, Marita continues to work on the cost-effectiveness of cervical cancer screening in Kenya, and other global health projects.

POST-DOCTORAL FELLOWS, cont.

PORPP /

JUNIOR FACULTY

CARRIE BENNETTE, PhD Acting Assistant Professor

Carrie is a K12 Scholar and Acting Assistant Professor in the Department of Pharmacy and an Affiliate Investigator at the Fred Hutchinson Cancer Research Center. She received her PhD from the University of Washington and completed postdoctoral training at the Fred Hutchinson and Group Health Research Institute before joining the UW faculty in early 2016. Before moving to Seattle, she worked as a biostatistician at Memorial Sloan Kettering Cancer Center and earned a masters degree from Columbia University in New York. Her research interests include developing methods and tools to inform uncertain and complex decisions in research priority setting and pharmaceutical policy. For her dissertation, Carrie de-veloped novel methods to estimate the expected risk and return for publicly funded cancer clini-cal trial proposals and inform the prioritization of NCI’s limited research resources. This work lev-eraged promising advances in value of information analyses and risk prediction to inform invest-

ment decisions within a large cancer clinical trials cooperative group. She also has a strong interest in using data visuali-zations and web-based tools to communicate complex information to decision makers in accessible formats. She taught a new short course on the Principles of Effective Data Visualization at the Society for Medical Decision Making last year and is currently building a user-friendly and web-based interface for the methods she developed in her dissertation. Carrie’s recent research focuses on informing the design of payment systems for anticancer therapies so as to foster pharmaceutical innovation and improve the affordability of these treatments for patients and society. Specifically, she plans to evaluate the clinical and economic consequences of a series of recently enacted state laws to reduce out-of-pocket costs for oral chemotherapy and study how Medicare Part D impacted pharmaceutical innovation in the market for oral chemotherapy. Carrie was recently selected as a finalist for the prestigious NIH Director’s Early Independence Award to pursue this line of research. Carrie believes that PORPP is a very special place and cherishes the collegiality and her relationships with the other faculty and students in the program.

Student Publications & Posters

BLYTHE ADAMSON Bounthavong M, Adamson B, Basu A. Instrumental Variables: A Tool to Reduce Bias in Non-Randomized Studies. Value and Outcomes Spotlight. 2016 Feb;2(1) 24-25.

MARK BOUNTHAVONG Bounthavong M, Li M, Watanabe JH. An evaluation of health care expenditures in Crohn's disease using the United States Medical Ex-penditure Panel Survey from 2003 to 2013. Res Social Adm Pharm. 2016 May 20. pii: S1551-7411(16)30093-6. doi: 10.1016/j.sapharm. 2016.05.042. [Epub ahead of print] Wong SF, Bounthavong M, Nguyen CP, Chen T. Outcome Assess-ments and Cost Avoidance of an Oral Chemotherapy Management Clinic. J Natl Compr Canc Netw. 2016 Mar;14(3):279-85.

ELIZABETH BROUWER Nugent R, Brouwer E. Economic Benefit-Cost Analysis of Select Sec-ondary Prevention Interventions in LMIC. Global heart. 2015 Dec 31;10(4):319-21. Watkins D, Poggio R, Augustovski F, Brouwer E, Riviere AP, Rubin-stein A, Nugent R. The Cost-Effectiveness of Interventions and Policies for Noncommunicable Diseases and Their Risk Factors in the Latin America and Caribbean Region: A Systematic. Economic Dimensions of Noncommunicable Diseases in Latin America and the Caribbean. 2016:87. Brouwer ED, Watkins D, Olson Z, Goett J, Nugent R, Levin C. Provider costs for prevention and treatment of cardiovascular and related condi-tions in low-and middle-income countries: a systematic review. BMC public health. 2015 Nov 26;15(1):1.

SIMRUN GREWAL Ozawa, S., Grewal, S., & Bridges, J. F. (2016). Household Size and the Decision to Purchase Health Insurance in Cambodia: Results of a Dis-crete-Choice Experiment with Scale Adjustment. Applied health eco-nomics and health policy, 14(2), 195-204.

Ozawa, S., Clark, S., Portnoy, A., Grewal, S., Brenzel, L., & Walker, D.

G. (2016). Return On Investment From Childhood Immunization In Low-

And Middle-Income Countries, 2011–20. Health Affairs, 35(2), 199-207. / UNIVERSITY OF WASHINGTON SCHOOL OF PHARMACY

Students

Blythe Adamson

Pre-Doctoral Fellowship in Pharmaceutical Sciences from

the American Foundation for Pharmaceutical Education

Student Technology Finalist Prize for "Cloud Connected System

for Augmenting Existing Rapid Diagnostic Test Performance" from the Massachusetts General Hospital Ambulatory Practice of the Future, sponsored by the Gelfand Family Charitable Trust

Scholarship Recipient, Reducing Barriers for the Ambitious Fund

Husky 100 Award. University of Washington. Selected as one of

100 students, among 43,000 students across 3 University of Washington campuses, for capturing the Husky Experience and academic pillars.

William Canestaro

JMCP 2015 Award for Excellence for his paper, “Improving the

Efficiency and Quality of the Value Assessment Process for Com-panion Diagnostic Tests: The Companion test Assessment Tool, (CAT)”

PORPP Endowed Prize in Health Policy and Economics (Co-

Recipient)


Amy Cizik


Devender Dhanda

School of Pharmacy Magnuson Scholar Award

Horacio Duarte

Scholarship for the 2016 Summer Institute in Statistics & Modeling

in Infectious Diseases

Laura Hart

2016-2017 UW Retirement Association Graduate Student Fellow-

ship in Aging

ACCP Research Institute Futures Grant to support thesis research

Cate Lockhart

2016 Ocular Toxicology Specialty Section-Covance-OSOD Gradu-

ate Student/Postdoctoral Fellow Research Award

Young Scholar Award, Dove Medical Press LTD for work on the

pathophysiology of Bietti’s crystalline dystrophy (BCD)

Solomon Lubinga


Sheila Shapouri

Washington State Student Pharmacist of the Year (Awarded by

Washington State Pharmacy Association; Annual Meeting-November 2015)

Kangho Suh

2016 ISPOR Student Travel Grant

Amy Tung

ISPOR 21st Annual International Meeting Research Presentation

Award Finalist

Elisabeth Vodicka

PORPP Endowed Prize in Health Policy and Economics (Co-

Recipient)

Scholarship Recipient, Human Rights to Family Planning Confer-

ence, Seattle, WA


Faculty & Post-Docs

Aasthaa Bansal

Best Poster Presentation: New Investigator, ISPOR 21st Annual

International Meeting

Anirban Basu

Research Excellence Award for Methodological Excellence, Inter-

national Society for Pharmacoeconomics and Outcomes Re-search (ISPOR) 2016

Fellow, American Statistical Association 2016

Carrie Bennette

Top Reviewer, Annals of Internal Medicine, 2016

Finalist, NIH Director’s Early Independence Award, 2016

Zachary Marcum

K12 Scholar, Patient Centered Outcomes Career Development

Joshua Roth

Best New Investigator Podium Research Presentation, ISPOR

21st Annual International Meeting Kai Yeung

Best Student Paper of the Year, Vancouver Health Economics

Methodology (VanHEM) Annual Meeting, June 2016

Honorable Mention Best Paper of the Year, Journal of Managed

Care & Specialty Pharmacy, April 2016

HONORS AND AWARDS

POST-DOC PUBLICATIONS

SOUVIK BANERJEE Banerjee S, Chatterji P, Lahiri K. Effects of Psychiatric Disorders on Labor Market Outcomes: A Latent Variable Approach Using Multiple Clinical Indicators. Health Economics, 2015, doi: 10.1002/hec.3286

KAI YEUNG Yeung K, Basu A, Hansen RN, Sullivan SD. Price elastiticies of pharmaceuticals in a value-based-formulary setting. National Bu-reau of Economic Research Working Paper #22308, June 2016

MARITA ZIMMERMANN Mann, M, A Mengistu, J Gaeseb, E Sagwa, G Mazibuko, J Baeten, JB Babigumira, LG Garrison, and A Stergachis. 2016. “Sentinel Site Active Surveillance of the Safety of First-Line Antiretrovi-ral Medicines in Namibia.” Pharmacoepidemiol Drug Saf. doi:10.1002/pds.4022. Mann, Marita, Assegid Mengistu, Johannes Gaeseb, Evans Sag-wa, Greatjoy Mazibuko, Joseph B. Babigumira, Louis P. Garrison, and Andy Stergachis. 2016. “Active Surveillance versus Spontane-ous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost–Utility Analysis.” Drug Safety. doi:10.1007/s40264-016-0432

Dufort, Elizabeth M., Allison K. DeLong, Marita Mann, Winstone M. Nyandiko, Samuel O. Ayaya, Joseph W. Hogan, and Rami Kantor. 2016. “Misclassification of Antiretroviral Treatment Failure Using WHO 2006 and 2010/2013 Immunologic Criteria in HIV-Infected Children and Adolescents in Western Kenya: Table 1.” Journal of the Pediatric Infectious Diseases Society, piw018. doi:10.1093/jpids/piw018.

ERIK LANDAAS

Landaas EJ, Franklin G, Thompson J, Lessler D, Morse J, Mootz R, Hammond GS, Sullivan, SD. (2016). Expanding Evidence-Based Technology Assessment for Coverage in Washington State. International Journal of Technology Assessment in Health Care, publishing in 2016.

MENG LI

Bounthavong M, Li M, Watanabe JH. An evaluation of health care expenditures in Crohn's disease using the United States Medical Expenditure Panel Survey from 2003 to 2013. Res Social Adm Pharm. 2016 May 20. [Epub ahead of print] Montenovo MI, Jalikis FG, Li M, Yeh M, Sibulesky L, Dick A, Han-sen R, Reyes JD. Superior Patient and Graft Survival in Adult Liver Transplantation with Rabbit Anti-thymocyte Globulin Induction: Experience with 595 Patients. Exp Clin Transplant. 2016 Jun 15. [Epub ahead of print] Sibulesky L, Li M, Hansen RN, Dick AAS, Martin MI, Rayhill S, Bakthavatsalam R, Reyes, JD. Impact of Cold Ischemia Time on Outcomes of Liver Transplantation: A Single Center Experience. Ann of Transplant. 2016 Mar 8;21:145-51

SOLOMON LUBINGA Katusiime B, Semakula D, Lubinga SJ. Adverse drug reaction reporting among health care workers at Mulago National Referral and Teaching hospital in Uganda. Afr Health Sci. 2015;15(4):1308-17 Lubinga SJ, Atukunda EC, Wasswa-Ssalongo G, Babigumira JB. Potential Cost-Effectiveness of Prenatal Distribution of Misoprostol for Prevention of Postpartum Hemorrhage in Uganda. PLoS One. 2015;10(11):e0142550 Watkins D, Lubinga SJ, Mayosi B, Babigumira JB. A Cost-Effectiveness Tool to Guide the Prioritization of Interventions for Rheumatic Fever and Rheumatic Heart Disease Control in African Nations. PLoS NTDs. In Press

MICHAEL SERBIN Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis. JMCP. Pending publication (August 2016)

SHEILA SHAPOURI Bakken TE, Miller JA, Ding SL, Sunkin SM, Smith KA, Ng L, Szafer A, Dalley RA, Royall JJ, Lemon T, Shapouri S, Aiona K. et al. A comprehensive transcriptional map of primate brain development. Nature. 2016;535(7612): 367-75.

KANGHO SUH Gold LS, Suh K, Schepman PB, Damal K, Hansen RN. Healthcare costs and resource utilization in patients with multiple sclerosis relapses treated with H.P. Acthar Gel. Adv Ther 2016 Jun [Epub ahead of print] POSTER Suh K, Carlson JJ, Garrison LP. Projecting the potential cost-effectiveness of ocrelizumab versus standard care in primary pro-gressive multiple sclerosis patients under alternative pricing sce-narios. ISPOR 21st Annual International Meeting May 21-25. Washington, DC, USA

ELISABETH VODICKA Vodicka E, Eller N, Stergachis A, Wasserheit J, Zunt JR, Garcia PJ. Assessing Preferences for and Feasibility of Using Pharmacies for Hypertension Management in Lima, Peru. Poster session pre-sented at: AcademyHealth; June 26, 2016; Boston, MA. Vodicka E, Babigumira JB, Mann M, Kosgei RJ, Lee F, Mugo N, Okech T, Sakr S, Garrison LP, Chung MH. Costs of Cervical Can-cer Treatment Integrated into HIV Care in Nairobi, Kenya. Poster session presented at: Annual Symposium for Global Cancer Re-search; April 8, 2016; San Francisco, CA. POSTERS Vodicka E, Eller N, Stergachis A, Wasserheit J, Zunt JR, Garcia PJ. Assessing Preferences for and Feasibility of Using Pharmacies for Hypertension Management in Lima, Peru. Poster session pre-sented at: AcademyHealth; June 26, 2016; Boston, MA.

PORPP FACULTY RECENT PUBLICATIONS

JOSEPH BABIGUMIRA Akullian AN, Mukose A, Levine GA, Babigumira JB: People living with HIV travel farther to access healthcare: a population-based geographic analysis from rural Uganda. J Int AIDS Soc 2016, 19:20171. Nevin PE, Pfeiffer J, Kibira SP, Lubinga SJ, Mukose A, Babigumi-ra JB: Perceptions of HIV and Safe Male Circumcision in High HIV Prevalence Fishing Communities on Lake Victoria, Uganda. PLoS One 2015, 10:e0145543. Othieno C, Babigumira JB, Richardson B: Are women with com-plications of an incomplete abortion more likely to be HIV infected than women without complications? BMC Womens Health 2015,

15:95.

AASTHAA BANSAL Bansal A, Radich JP (2016). Is cure for CML possible in the TKI era? Current Opinion in Hematology, 23(2): 115-120. Ramsey SD, Bansal A, Fedorenko CR, Blough DK, Overstreet KA, Shankaran V, Newcomb P. Financial insolvency as a risk fac-tor for early mortality among patients with cancer (2016). Journal of Clinical Oncology, 34(9): 980-986. Othus M, Bansal A, Koepl L, Wagner S, Ramsey S. Accounting for cured patients in cost-effectiveness analysis. Value in Health, in press.

ANIRBAN BASU Basu A, Subedi P, Kamal-Bahl S. Financing a cure for diabetes in a multi-payer environment. Value in Health 2016 In press. Basu A, Carlson JJ, Veenstra DL. A framework for prioritizing research investments in precision medicine. Medical Decision Making 2016 In Press. Basu A, Axelsen K, Grabaowski DC, Meltzer DO, Polsky D, Ridley DB, Wiederkehr D, Philipson TJ. Real World Data: Policy issues

HONORS AND AWARDS

Vodicka E, Babigumira JB, Mann M, Kosgei RJ, Lee F, Mugo N, Okech T, Sakr S, Garrison LP, Chung MH. Costs of Cervical Can-cer Treatment Integrated into HIV Care in Nairobi, Kenya. Poster session presented at: Annual Symposium for Global Cancer Re-search; April 8, 2016; San Francisco, CA.

PORPP /

PUBLICATIONS

2016

PORPP RETREAT

The 2016 PORPP Retreat celebrated 20 years of success with a day and a half agenda that included strategic planning, dinner at a Woodinville brewery, a lip-sync contest and wine tasting. Students, faculty, alumni and staff all contributed to the working sessions and the festivities. The strategic planning session laid the groundwork for the vision that will lead the program into the next decade. Some of the areas that both students and faculty identified as being important to the future development and vision include:

Provide state-of-the-art education and training

Research Leaders (Be a global leader in generating knowledge)

Health Economics & Outcomes Research/Pharmacoeconomic Outcomes Research

Impact Healthcare Value

Change name of program

Become a “center” or “institute” within the university hierarchy system

Develop actionable knowledge The Retreat ended on an optimistic note, with many meaningful, thoughtful and positive suggestions to carry the program forward into the future.


regarding their access and use. Medical Care 2016 In press.

CARRIE BENNETTE Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL. Predicting low accrual in the National Cancer Insti-tute’s Cooperative Group Clinical Trials . Journal of the National Cancer Institute. 2015 Dec 29;108(2). Bennette CS, Veenstra DL, Basu A, Baker L, Ramsey SD, Carl-son JJ. Development and evaluation of an approach to using Val-ue of Information Analyses for real-time prioritization decisions within SWOG-a large clinical trials cooperative group. Medical Decision Making. July 2016. 36 (5), 641-651. Bennette CS, Richards C, Sullivan SD, Ramsey SD. Steady In-crease In Prices For Oral Anticancer Drugs After Market Launch Suggests A Lack Of Competitive Pressure. Health Affairs. May 2016 vol. 35 no. 5 805-812

DENISE BOUDREAU Calip GS, Yu O, Elmore JG, Boudreau DM. Comparative Safety of Diabetes Medications and Risk of Incident Invasive Breast Cancer: A Population-Based Cohort Study. Cancer Causes & Control. 2016 Apr 6. [Epub ahead of print] Roth JA, Bradley K, Thummel KE, Veenstra DL, Boudreau D. Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting. Pharmacoepidemiol Drug Saf. 2015;24:619-27. Arterburn D, Sofer T, Boudreau DM, Bogart A, Westbrook EO, Theis MK, Simon GE, Haneuse S. Long-term weight change after initiating second-generation antidepressants. J Clin Med. 2016 Apr 13;5(4).

BRIAN BRESNAHAN Duong PA, Bresnahan B, Pastel DA, Sadigh G, Ballard D, Sulli-van JC, Buch K, Duszak R Jr., Value of Imaging Part I: Perspec-tives for the Academic Radiologist, Acad Radiol. 2016 Jan;23(1):18-22. doi: 10.1016/j.acra.2015.10.006. Epub 2015 Nov 10, PMID: 26683508. Roudsari B, McWilliams J, Bresnahan BW, Padia S, Introduction to cost analysis in interventional radiology: challenges and oppor-tunities, J Vasc Interv Radiol. 2016 Feb 25. pii: S1051-0443(15)02009-6. doi: 10.1016/j.jvir.2015.12.754. [Epub ahead of print] Review. PMID: 26922978.

JOSH CARLSON Yu JS, Hansen RN, Valderrama A, Carlson JJ. Indirect costs and workplace productivity loss associated with non-Hodgkin lympho-ma. Leuk Lymphoma. 2016:1-8. Bennette CS, Veenstra DL, Basu A, Baker LH, Ramsey SD, Carl-son JJ. Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Deci-sions Within SWOG, a Large Cancer Clinical Trials Cooperative Group. Med Decis Making. 2016. Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL. Predicting Low Accrual in the National Cancer Insti-tute's Cooperative Group Clinical Trials. J Natl Cancer Inst. 2016;108(2). Basu A, Carlson JJ, Veenstra DL. A Framework for Prioritizing Research Investments in Precision Medicine. Med Decis Making. Oct 26 2015; ePub.

BETH DEVINE Devine EB, Alfonso-Cristancho R, Yanez ND, Edwards TC, Pat-rick DL, Armstrong CAL, Devlin A, Symons RG, Meissner MH, Thomason EL, Lavallee DC, Kessler LG, Flum DR, and CERTAIN Collaborative. Patient-Reported Outcomes after Medical versus Revascularization Interventions for Intermittent Leg Claudication. (in press at JAMA Surg, August 2016) Canestaro WJ, Forrester SH, Devine EB. Drug therapy for treat-ment of idiopathic pulmonary fibrosis: Systematic review and net-work meta-analysis. Chest 2016;149(3):756-66 Agapova M, Garrison LP, Bresnahan B, Johnson R, Higashi M, Kessler L, Devine EB. Development of a decision aid for quantita-tive evaluation of benefits and risks in diagnostic imaging. (in press at J Eval Clin Pract, August 2016)

LOUIS GARRISON, JR. Garrison LP. Cost-Effectiveness and Clinical Practice Guide-lines: Have We Reached a Tipping Point?—An Overview. Value in Health, July-August 2016

Garrison LP Jr, Carlson JJ, Bajaj PS, Towse A, Neumann PJ, Sullivan SD, Westrich K, Dubois RW. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. Am J Manag Care. 2015 Sep;21(9):632-40. Garrison LP Jr, Lewin J, Young CH, Généreux P, Crittendon J, Mann MR, Brindis RG. The clinical and cost burden of coronary calcification in a Medicare cohort: An economic model to address under-reporting and misclassification. Cardiovasc Revasc Med. 2015 Oct-Nov;16(7):406-12.. Epub 2015 Aug 12.

SHELLY GRAY Gray SL, Dublin S, Yu O, Walker R, Anderson M, Crane P, Larson E Benzodiazepine use and risk of incident dementia or cognitive decline. BMJ. 2016;352:i90 PMC4737849 Golchin N, LaCroix A, Hohensee C, Gray SL. Nitrate medication use, fractures and change in bone mineral density in postmeno-pausal women: Results from the Women’s Health Initiative. J Bone Min Research. 2016 11 JUL 2016 DOI: 10.1002/jbmr.2838 Marcum Z, Wirtz HS, Pettinger M, LaCroix A, Carnahan R, Cauley JA, Bea J, Gray SL. Anticholinergic medication use and falls in postmenopausal women. BMC Geriatrics 2016;16:76.

RYAN HANSEN Farias AJ, Hansen RN, Zeliadt SB, Ornelas I, Li C, Thompson B. The association between out-of-pocket costs and adherence to adjuvant endocrine therapy among newly diagnosed breast cancer patients. American Journal of Clinical Oncology 2016. In Press. Dilokthornsakul P, Hansen RN, Campbell JD. Forecasting US Ivacaftor Outcomes and Cost in Cystic Fibrosis Patients with G551D Mutation. European Respiratory Journal 2016;47(6):1697-1705. Hoogendoorn M, Feenstra TL, Asukai Y, Briggs AH, Borg S, Dal Negro RW, Hansen RN, Jansson S, Leidl R, Risebrough N, Samyshkin Y, Wacker ME, Rutten-van Molken MPMH. Patient heterogeneity in health economic decision models for chron-ic obstructive pulmonary disease (COPD): are current models suitable to evaluate personalized medicine? Value In Health 2016. In Press.

LOTTE STEUTEN Miquel-Cases A, Retèl VP, van Harten WH, Steuten LM. Deci-sions on Further Research for Predictive Biomarkers of High-Dose Alkylating Chemotherapy in Triple-Negative Breast Cancer: A Val-ue of Information Analysis. Value Health. 2016 Jun;19(4):419-30. doi: 10.1016/j.jval.2016.01.015. Epub 2016 Apr 6. PubMed PMID: 27325334. Steuten LM. Multi-Dimensional Impact of the Public-Private Cen-ter for Translational Molecular Medicine (CTMM) in the Nether-lands: Understanding New 21(st) Century Institutional Designs to Support Innovation-in-Society. OMICS. 2016 May;20(5):265-73. doi: 10.1089/omi.2016.0042. PubMed PMID: 27195965; PubMed Central PMCID: PMC4876525. Oosterhoff M, van der Maas ME, Steuten LM. A Systematic Re-view of Health Economic Evaluations of Diagnostic Biomarkers. Appl Health Econ Health Policy. 2016 Feb;14(1):51-65. doi: 10.1007/s40258-015-0198-x. PubMed PMID: 26334528; PubMed Central PMCID: PMC4740568.

LARRY KESSLER Friedly JL, Comstock BA, Turner JA, Heagerty PJ, Deyo RA, Sulli-van SD, Bauer Z, Bresnahan BW, Avins AL, Nedeljkovic SS, Ne-renz DR, Standaert C, Kessler L, Akuthota V, Annaswamy T, Chen A, Diehn F, Firtch W, Gerges FJ, Gilligan C, Goldberg H, Kennedy DJ, Mandel S, Tyburski M, Sanders W, Sibell D, Smuck M, Wasan A, Won L, Jarvik JG. A randomized trial of epidural glucocorticoid injections for spinal stenosis. N Engl J Med. 2014 Jul 3;371(1):11-21. doi: 10.1056/ NEJMoa 1313265. PMID: 24988555 Flum DR, Alfonso-Cristancho R, Devine EB, Devlin A, Farrokhi E, Tarczy-Hornoch P, Kessler L, Lavallee D, Patrick DL, Gore JL, Sullivan SD; CERTAIN Collaborative. Implementation of a "real-world" learning health care system: Washington state's Compara-tive Effectiveness Research Translation Network (CERTAIN). Sur-gery. 2014 May;155(5):860-6. doi: 10.1016/j.surg.2014.01.004. PMID: 24787113

PORPP /

PUBLICATIONS

Faculty — Recent Grants

Jarvik JG, Comstock BA, Heagerty PJ, Turner JA, Sullivan SD, Shi X, Nerenz DR, Nedeljkovic SS, Kessler L, James K, Friedly JL, Bresnahan BW, Bauer Z, Avins AL, Deyo RA. Back pain in sen-iors: the Back pain Outcomes using Longitudinal Data (BOLD) cohort baseline data. BMC Musculoskelet Disord. 2014 Apr 23;15(1):134. doi: 10.1186/1471-2474-15-134. PMID: 24755158 PMCID: PMC4021204

DANIELLE LAVALLEE Ehlers AP, Davidson GH, Bizzell BJ, Guiden MK, Skopin E, Flum DR, Lavallee DC. Engaging Stakeholder in Surgical Research: The Design of a Pragmatic Clinical Trial to Study Management of Acute Appendicitis. JAMA Surg. 2016 Feb 24. PMID: 26914789. Lavallee DC, Chenok KE, Love RM, Petersen C, Holve E, Segal CD, Franklin PD. Incorporating Patient-Reported Outcomes Into Health Care To Engage Patients And Enhance Care. Health Aff. 2016 April 1. PMID: 27044954

ZACHARY MARCUM Marcum ZA, Perera S, Newman AB, Thorpe JM, Switzer GE, Gray SL, Simonsick EM, Shorr RI, Bauer DC, Castle NG, Studen-ski SA, Hanlon JT. Antihypertensive use and recurrent falls in community-dwelling older adults: findings from the Health ABC study. J Gerontol A Biol Sci Med Sci 2015;70:1562-8. Marcum ZA, Perera S, Thorpe JM, Switzer GE, Castle NG, Strotmeyer ES, Simonsick EM, Ayonayon HN, Phillips CL, Rubin S, Zucker-Levin AR, Bauer DC, Shorr RI, Kang Y, Gray SL, Hanlon JT. Antidepressant use and recurrent falls in community dwelling older adults: findings from the Health ABC study. Ann Pharmacother 2016;50:525-33. Marcum ZA, Wirtz HS, Pettinger M, LaCroix AZ, Carnahan R, Cauley JA, Bea JW, Gray SL. Anticholinergic medication use and falls in postmenopausal women: findings from the Women’s Health Initiative cohort study. BMC Geri 2016;16:76.

JOSH ROTH Roth JA, Ramsey SD, Carlson JJ. Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer. Oncologist. 2015 Dec;20(12):1355-64. doi: 10.1634/theoncologist.2015-0214. Epub 2015 Oct 19. PubMed PMID: 26482553; PubMed Central PMCID: PMC4679086. Roth JA, Ramsey SD. Computed Tomography Screening for Lung Cancer: A High-Value Proposition? JAMA. 2016 Jan 5;315(1):77-8. doi: 10.1001/jama.2015.17877. PubMed PMID: 26746460 Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies. JAMA Oncol. 2016 Mar 24. doi: 10.1001/jamaoncol.2015.6275. [Epub ahead of print] PubMed PMID: 27010943

SCOTT RAMSEY Unger, JM, Barlow WE, Ramsey SD, LeBlanc M, Blanke CD, Hershman DL. The Scientific Impact of Positive and Negative Phase 3 Cancer Clinical Trials. JAMA Oncol. 2016 Mar 10. doi: 10.1001/jamaoncol.2015.6487. [Epub ahead of print]. PMID: 26967260. Ramsey SD, Bansal A, Fedorenko CR, Blough DK, Overstreet K, Shankaran V, Newcomb P. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016 Mar 20;34(9):980-6. doi: 10.1200/JCO.2015.64.6620. Epub 2016 Jan 25. PMID: 26811521. Bennette CS, Veenstra DL, Basu A, Baker LH, Ramsey SD, et al. Development and Evaluation of an Approach to Us-ing Value of Information Analyses for Real-Time Prioritization De-cisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group. Med Decis Making. 2016 Mar 24. pii: 0272989X16636847. [Epub ahead of print]. PMID: 27012232

ANDY STERGACHIS

Tinto H, Sevene E, Dellicour S, Calip GS, d’Alessandro U, Macete E, Nakanabo-Diallo S, Kazienga A, Valea I, Sorgho H, Valá A, Augusto O, Ruperez M, Menendez C, Ouma P, Desai M, ter Kuile

F, Stergachis A. Assessment of the safety of antimalarial drug use during early pregnancy (ASAP): protocol for a multicenter prospective cohort study in Burkina Faso, Kenya and Mozam-bique. Reproductive Health. 2015 Dec, 12:112. Mann M, Mengistu A, Gaeseb J, Sagwa E, Mazibuko G, Babigumi-ra JB, Garrison LP, Stergachis A. Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost Utility Analysis. Drug Saf. 2016 Jun 17. [Epub ahead of print]. Moradi-Lakeh M, El Bcheraoui C, Daoud F, Tuffaha M, Wilson S, Al Saeedi M, Basulaiman M, Memish ZA, AlMazroa MA, Al Rabeeah AA, Stergachis A, Mokdad AH. Medication use for chronic health conditions among adults in Saudi Arabia: findings from a national household survey. Pharmacoepidemiol Drug Saf. 2016;25):73-81.

SEAN SULLIVAN McDougall JA, Bansal A, Goulart BH, McCune J, Karnopp A, Fe-dorenko C, Geenlee S, Valderama A, Sullivan SD, Ramsey SD. The Clinical and Economic Impacts of Skeletal Related Events Among Medicare Enrollees with Prostate Cancer Metastatic to Bone. The Oncologist 2016 Mar;21(3):320-6. Bennette CS, Richards C, Sullivan SD, Ramsey SD. Trends and determinants of oral anticancer drug costs after market introduc-tion. Health Affairs in press, 2016 Loggers ET, Buist DSM, Gold LS, Zeliadt S, Hunter-Merrill S, Etzioni R, Ramsey SD, Sullivan SD, Kessler LG. Advanced Imag-ing and Receipt of Guideline Concordant Care in Women with Early Stage Breast Cancer. Int J of Breast Cancer in press.

DAVID VEENSTRA Veenstra DL., The value of routine pharmacogenomic screening - Are we there yet? A perspective on the costs and benefits of rou-tine screening - shouldn't everyone have this done? Clin Pharma-col Ther. 2016 Feb;99(2):164-6. doi: 10.1002/cpt.299. Epub 2015 Dec 23.PMID: 26565561 Basu A, Carlson JJ, Veenstra DL.A Framework for Prioritizing Research Investments in Precision Medicine. Value Health. 2015 Nov;18(7):A729. doi: 10.1016/j.jval.2015.09.2777. Epub 2015 Oct 20. No abstract available. PMID: 26534083 Similar articles Se-lect item 26533910 Canestaro WJ, Pritchard DE, Garrison LP, Dubois R, Veenstra DL. Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT). J Manag Care Spec Pharm. 2015 Aug;21(8):700-12. Review. PMID: 26233542

DAVENE WRIGHT Wright DR, Lozano P, Dawson-Hahn EE, Christakis DA, Haaland WL, Basu A. Parental Predictions and Perceptions Regarding Long-Term Childhood Obesity-Related Health Risks. Academic Pediat-rics. July 2016; 16: 475-481. Wright DR, Haaland WL, Ludman E, McCauley E, Lindenbaum J, Richardson LP. The costs and cost-effectiveness of collaborative care for adolescents with depression in primary care settings. JA-MA Pediatrics [In Press] Lion KC, Wright DR, Spencer, Zhou C, Del Beccaro M, Mangione-Smith R. “Standardized Clinical Pathway Care and Improved Out-comes among Hospitalized Children.” Pediatrics. April 2016; 137(4): doi: 10.1542/peds.2015-1202. PMID: 27002007


AASTHAA BANSAL PI Comparative effectiveness of molecular response guided se-quential treatment strategies in chronic myeloid leukemia Sponsor: PhRMA Foundation 2015-2017 Co-I (PIs: Sullivan, Ramsey)A Pragmatic Trial to Improve Colony Stimulating Factor Use in Cancer Sponsor: PCORI 2015-2019

PUBLICATIONS & GRANTS

http://www.ncbi.nlm.nih.gov/pubmed/26967260

http://www.ncbi.nlm.nih.gov/pubmed/26967260

http://www.ncbi.nlm.nih.gov/pubmed/?term=Development+and+Evaluation+of+an+Approach+to+Using+Value+of+Information+Analyses+for+Real-Time+Prioritization+Decisions+Within+SWOG

Co-I (PI: Goulart) Assessing Molecular Profiling in Non-Small Cell Lung Cancer at the Population Level: A Validation Study of Natural Language Processing Algorithms for SEER Fred Hutchinson Cancer Research Center 2015 – 2016

ANIRBAN BASU Co-PI, (PI Coleman, Kaiser Permanente) NHLBI R01, Effective-ness of Gastric Sleeve vs. Gastric Bypass for Cardiovascular Dis-ease 2016-2019

DENISE BOUDREAU Co-PI, Extended Release/Long Acting Opioid Post-Marketing Re-quirement Studies: Observational Study 1A, Campbell Alliance, 2015-2016 Co-I, Co-Management and Health Impacts of Breast Cancer and Diabetes, NCI, 2015-2019 Co-I, FDA Sentinel-Infrastructure, FDA 2015-2016

BRIAN BRESNAHAN Co-Inv. (PI Friedly) Long Term Outcomes of Lumbar Epidural Steroid Injections for Spinal Stenosis Patient-Centered Out-comes Research Institute (PCORI) 2013 – 2016 PI, Economic analysis of an international, multi-site random-ized controlled trial of ultrasound screening? primary project sponsor (Bill and Melinda Gates Foundation).

JOSH CARLSON PI ICER Economic Modeling ; ICER, 1/2016-12/2017 Co-Investigator (Basu PI) Value of Information Methods for NHLBI Trials; NHLBI, 2015-2019 Co-Investigator (Veenstra PI), Personalized Medicine Economics Research (PriMER) NIH/NIAAA, 2013-2018

BETH DEVINE PI, UW-Allergan Post-Doctoral Fellowship, Allergan Pharma-ceuticals, 2012- Site PI, Pacific Northwest Evidence-based Practice Center (EPC) V, AHRQ, 2015-2019: 1) Medication Assisted Treatment (2016); 2) Treatment for Adults with Schizophrenia (2016-2017); 3) US Preventative Services Task Force (2016-2019) – a) BRCA-Related Cancer Risk Assessment/Genetic Testing; b) Breast Cancer – Medications for Risk Reduction Co-I, (PI: Thompson) Patient-Centered Research for Standards of Outcomes in Diagnostic Tests, PCORI Methods, 2015-2018

LOUIS GARRISON, JR. Principal Mentor, UW-Pfizer Post-Doctoral Fellowship, 2016-2018. PI, Estimating the Burden of Illness in Giant Cell Arteritis, Genen-tech, 2014-2016 Co-Inv. (PI-Chung) University of Nairobi HIV Capacity Building Fellowship. USAID, 2014-2018

SHELLY GRAY Co-Investigator, (Dublin PI), Opioids, benzodiazepines, general anesthesia & risk of suppression of NIV replication.. NIH, 2012-2015

RYAN HANSEN Royalty Research Fund: Legalization And recreational Marijuana effects on PoPulatiOn health and coSTs (LAMPPOST)

National Institute of Dental and Craniofacial Research (NIDCR): Oral Health Equity in Alaska (OHEAL): Implementation and Evaluation of Delivery System Changes to Reduce Oral Health Disparities for Native American Children

ZACHARY MARCUM Scholar; UW K12 in Patient-Centered Outcomes Research (Sullivan PI) – AHRQ , 08/2016-07/2019 Co-Investigator, (Dublin PI) AGING Initiative Pilot Projects Program Grant (Dublin PI) – HMORN-OAIC 01/2016-12/2016 Co-Investigator; (Gray PI) Elmer M. Plein Endowed Research Fund 01/2016-12/2016

PORPP /

JOSH ROTH Co-PI (PI Gilliland) CCSG Pilot Award, FHCRC, NCI, 2015-2016

SCOTT RAMSEY PI: Ramsey PCORI A Pragmatic Trial to Improve Colony Stimulat-ing Factor Use in Cancer 07/01/15 – 03/31/21 (award received 9/15) PCS-1402-09988 PI: Mandelblatt, Ramsey, Lieu, Georgetown University/NIH, Optimizing personalized care using economic studies of ge-nomic testing – Admin Supplement 09/01/15 – 08/31/17 U01 CA183081-02S1

LOTTE STEUTEN PI; Merkel Cell Carcinoma Burden of Disease Study in the US, EMD Serono, 02/2016-12/2016 Co-PI (PI-Hsu); Statistical Methods for Genetic Epidemiologic Studies; NIH/NCI, 2015-2019 Co-I (PI: Feng/Thornquist/Pepe), The Early Detection Research Network: Data Management and Coordinating Center; NIH/NCI 2000-2021

ANDY STERGACHIS PI, Malaria Elimination Safety Study Group, Liverpool School of Tropical Medicine/Worldwide Malaria Resistance Network, 9/2015-12/2016. PI, Technical Assistance for Pharmacovigilance in Afghanistan, Management Sciences for Health/USAID, 11/2015-05/2017. PI, Maternal Immunization Pharmacovigilance in Low and Middle-Income Countries, Global Alliance to Prevent Prematurity and Stillbirth (GAPPS), 7/2016-6/2017.

SEAN SULLIVAN

PI, CHASE K12 Training, 2014-2019, AHRQ

Co-Inv. (PI Linda Teri) From Evidence-Base to Practice: Imple-menting RDAD in AAA Community-Based Services. (National Institute of Aging) PI, K-12 Mentored Career Development Program in Patient-Centered Outcomes Research (AHRQ) July 2012 to June 2014. Co-Director, Pacific Northwest Evidence-Based Practice Center (AHRQ) August 2012 to July 2017 Co-Investigator, (PI-Ramsey) Pragmatic Trial of Pharmacist-based Guideline Use of CSF; PCORI; 2015-2019

DAVID VEENSTRA

Co-Inv. (PI Sullivan) CHASE K12 Training, 2014-2019 AHRQ

Co-Inv. (PI Burke) Center for Genomics and Healthcare Equality,

2010-2015, NIH/NGRI

Co-Inv. (PI Thummel) Pharmacogenetics in Rural and Under-served Populations, 2010-2015, NIGMS

DAVENE WRIGHT

PI Improving Parental Obesity-Related Risk Assessment Funded by NHLBI K01 HL130413 03/2016-02/2021 Consultant, (PI Austin) The Economic Case for Eating Disorders Prevention and Early Detection: A Comparative Cost-Effectiveness Analysis of Six Intervention Strategies Funded by the National Eating Disorders Association 01/2016-12/2017



PORPP would like to acknowledge our many sup-porters of this past year. Our accomplishments would not have been possible without these generous edu-cational grants and gifts.

Allergan

Alnylam Pharmaceuticals

Anirban Basu

Bayer AG

Benevity

Biogen Idec

Jonathan & Christina Campbell

Josh & Amy Carlson

James T. Cross

Beth Devine

Eli Lilly & Company

Louis and Fran Garrison, Jr.

GE Foundation

Thomas Hazlet

Mitchell & Mandy Higashi

Ipsen Pharma

Pfizer Inc.

Shelby & Steve Reed

Joshua Roth & Meghann Glavin

Shire Pharmaceuticals

Julia Slejko

Andy and JoAnn Stergachis

Sean and Catrena Sullivan

David and Julie Veenstra

William Wong

PORPP Health Technology Fund (Eli Lilly, GE Healthcare, Genentech, Glaxo- SmithKline, Novartis, Ortho-McNeil, Pfizer, Roche, Sanofi-Aventis)

GIFTS


Pharmaceutical Outcomes Research & Policy Program

Department of Pharmacy, University of Washington

Box 357630, Seattle, WA 98195-7630 Phone: 206-616-1383

Fax: 206-543-3835 Email: [email protected]

http://sop.washington.edu/porpp

RECOLLECTIONS FROM CAB, 2015

Beth Devine, Amy Tung and Jan Hansen enjoying the Don James Center.

Lou Garrison and Justin Yu on the Husky football field showing their moves.

CAB members Newell McElwee, Todd Williamson, Vipan Sood, Jan Hansen and Michael del Aguila “roasting” the newly minted Dean Sullivan.

Anirban Basu, Souvik Banerjee, Lou Garrison, Meng Li and Jean McDougall enjoying the CAB Poster reception

pharmaceutical outcomes research & …...lou garrison, phd, assumes the role of president for...

Documents